齐多夫定-拉米夫定与洛匹那韦-利托那韦联合用于HIV感染暴露后预防的耐受性
Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
作者信息
Rabaud Christian, Burty Christine, Grandidier Michel, Christian Bernard, Penalba Christian, Béguinot Isabelle, Jeanmaire Henri, May Thierry
机构信息
Centre d'Information et de Soins sur l'Immunodeficience Humaine, Lorraine Champagne-Ardenne, France.
出版信息
Clin Infect Dis. 2005 Jan 15;40(2):303-5. doi: 10.1086/426589. Epub 2004 Dec 21.
Tolerability of the combination of zidovudine-lamivudine and lopinavir-ritonavir as postexposure prophylaxis (PEP) for human immunodeficiency virus infection was prospectively assessed. A total of 121 patients were enrolled in the study; 23 patients discontinued PEP prematurely for reasons other than adverse events. Of the other 98 patients, 58 (59%) experienced adverse effects, which led to premature PEP discontinuation in 20 cases (20%).
前瞻性评估了齐多夫定-拉米夫定与洛匹那韦-利托那韦联合用药作为人类免疫缺陷病毒感染暴露后预防（PEP）的耐受性。共有121名患者纳入该研究；23名患者因不良事件以外的原因提前停止了PEP。在其他98名患者中，58名（59%）出现了不良反应，其中20例（20%）导致PEP提前停药。
Zotero 插件